Table 4:
Summary of studies of cost effectiveness of breast cancer screening in women of other age groups. All the studies used secondary data for modeling
| Author, year | Country | Perspective | Model | Intervals, age groups | Results* |
|---|---|---|---|---|---|
| Hall et al., 1992 (20) | Australia | Health system | Decision tree | Biennial 45–69 years | $7190 |
| Carter et al., 1993 (39) | Australia | Health system | MISCAN | Annual 40–49 plus biennial 50–69; Biennial 40–49 plus triennial 50–69; Biennial 40–69 |
$ 27257 $19919 $20300 |
| Rosenquist et al., 1994 (31) | USA | Health system | Markov | Annual 40–85; Annual 50–85 |
$18600 $16800 |
| Lindfors et al., 1995 (34) | USA | Health system | Markov | Seven different age group scenarios | From $16000 to $31900 |
| Szeto et al., 1996 (50) | New Zealand | Health system | MICROLIFE | Biennial 45–64 | $15169 |
| Rosenquist et al., 1998 (35) | USA | Societal | Markov | Four different age group scenarios | From $16100 to $18800 |
| Woo et al., 2007 (29) | Hong Kong | Societal | Decision tree | Biennial 50–74; Biennial 40–74; Annual 50–74; Annual 40–74 |
$90771, $107310, $321608, $385092, per DALY averted |
| Wong et al., 2007 (30) | Hong Kong | Societal | Markov | Biennial 40–69 | $64400, or $61600 per QALY gained |
| Okonkwo et al., 2008 (28) | India | Health system | MISCAN | Once at age 40; Biennial 40–60 |
$6496, and $3468; or $110542 and $46021 per death averted |
| Lee et al., 2009 (52) | Korea | Health system | Stochastic | Triennial 45–65 | $100007 per cancer detected |
*
Reported costs are “per life year gained” unless otherwise specified.